Considerations for Outsourcing Stability Storage - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Considerations for Outsourcing Stability Storage

Equipment and Processing Report

Untitled Document

Q. Our company needs more stability storage. What issues should we consider when deciding whether to build our own biorepository facility or outsource our storage?

A. In addition to questions of location, available facility space, and capital-equipment cost, as discussed in an article in September’s Equipment and Processing Report, you should consider the time and expertise needed to maintain regulatory compliance. Any cGMP facility should incorporate chambers and rooms that are built using the most modern techniques. They must be mapped and validated for pharmaceutical stability storage and biotechnology product storage. Outsourcing companies can tailor these temperature and humidity-controlled rooms and chambers to suit individual customer requirements, as well as to accomodate shelf-life studies, intermediate testing, and accelerated testing per International Conference on Harmonization’s (ICH) Q1A (R2) (1).

The assessment of drug-substance stability is a vital and essential aspect of the development of pharmaceutical products. Stability testing is capable of providing information on how environmental factors such as temperature, humidity, and light affect a product’s quality over a period of time. Data derived from a stability study enables recommended storage conditions, retest intervals, and shelf lives to be evaluated and established.

It is the norm for controlled environment rooms to be built and validated to provide climatic conditions specified in ICH guidelines. Rooms should include equipment to allow for simulating conditions in all four climatic zones for long-term, intermediate, and accelerated testing. An outsourcing facility should have a comprehensive range of conditions including ICH Photostability Option 1 and Option 2 studies, as well as the capacity for customization. All staff should be fully accountable and provide a service that complies with regulatory requirements.

Reference

  1. ICH, Q1A (R2), Stability Testing of New Drug Substances and Products (2003).

—Patrick Jackson is business development director at Vindon Scientific.

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Jennifer Markarian, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here